Search

Your search keyword '"treatment rebound"' showing total 3 results
Start Over Descriptor "treatment rebound"
3 results on '"treatment rebound"'

1. Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment

Author

Carlin, Aaron F, Clark, Alex E, Chaillon, Antoine, Garretson, Aaron F, Bray, William, Porrachia, Magali, Santos, AsherLev T, Rana, Tariq M, and Smith, Davey M

Subjects
Lung, Infectious Diseases, Prevention, Pneumonia & Influenza, Emerging Infectious Diseases, Immunization, Vaccine Related, Pneumonia, Biodefense, Good Health and Well Being, Humans, COVID-19, SARS-CoV-2, Ritonavir, COVID-19 Drug Treatment, treatment rebound, COVID-19 recrudescence, nirmatrelvir, Omicron, Biological Sciences, Medical and Health Sciences, Microbiology
Abstract

We isolated a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2 variant from a person with coronavirus disease 2019 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing were performed with both parental SARS-CoV-2 and multiple variants of concern. We found that neither nirmatrelvir resistance nor absence of neutralizing immunity was a likely cause of the recrudescence.

Published
2023

2. Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment

Author

Aaron F Carlin, Alex E Clark, Antoine Chaillon, Aaron F Garretson, William Bray, Magali Porrachia, AsherLev T Santos, Tariq M Rana, and Davey M Smith

Subjects
Microbiology (medical), Ritonavir, SARS-CoV-2, Omicron, nirmatrelvir, Prevention, COVID-19, Pneumonia, Biological Sciences, Medical and Health Sciences, Microbiology, COVID-19 Drug Treatment, Vaccine Related, Infectious Diseases, Emerging Infectious Diseases, Good Health and Well Being, Biodefense, COVID-19 recrudescence, Pneumonia & Influenza, Humans, treatment rebound, Immunization, Lung
Abstract

We isolated a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2 variant from a person with coronavirus disease 2019 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing were performed with both parental SARS-CoV-2 and multiple variants of concern. We found that neither nirmatrelvir resistance nor absence of neutralizing immunity was a likely cause of the recrudescence.

Published
2023

3. Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment.

Author

Carlin, Aaron F, Carlin, Aaron F, Clark, Alex E, Chaillon, Antoine, Garretson, Aaron F, Bray, William, Porrachia, Magali, Santos, AsherLev T, Rana, Tariq M, Smith, Davey M, Carlin, Aaron F, Carlin, Aaron F, Clark, Alex E, Chaillon, Antoine, Garretson, Aaron F, Bray, William, Porrachia, Magali, Santos, AsherLev T, Rana, Tariq M, and Smith, Davey M

Abstract

We isolated a SARS-CoV-2 BA.2 variant from a person with COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing were performed with both parental SARS-CoV-2 and multiple variants of concern. We found that neither NM resistance nor absence of neutralizing immunity were likely causes of the recrudescence.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results